ReST THERAPEUTICS

ReST Therapeutics is developing FENM (Fluoroethylnormemantine), a proprietary molecule, initially designed as a biomarker for NMDA receptor and derived from Memantine (ebixa®), the sole marketed drug partly efficient for moderate to severe forms of Alzheimer Disease. ReST Therapeutics mission is to bring FENM to Clinical POC for Post Traumatic Disorders (PTSD) following assault and Alzheimer, while investigating opportunities in Parkinson and extending its portfolio of fluoroethyl analogues.

Medicine